You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ acquires rare disease specialist Alexion

AstraZeneca (AZ) has announced plans to acquire Alexion for approximately $39bn, gaining an ‘innovative’ rare disease pipeline in the process.